Synvisc OA Therapy Boosts Margins, Holds Promise For New Indications
This article was originally published in The Gray Sheet
Executive Summary
Genzyme's recent reacquisition of marketing rights to the Synvisc knee osteoarthritis treatment will help the firm realize a hefty gross margins increase in 2005
You may also be interested in...
Genzyme reacquires Synvisc rights
Genzyme will pay Wyeth $121 mil. up-front, plus up to $294 mil. in milestones by 2012 to buy back marketing rights to the hyaluronic acid-based knee osteoarthritis treatment for the U.S. and certain European countries. Genzyme, which already markets Synvisc in the UK, France, Canada and Australia, estimates worldwide Synvisc sales at $240 mil. for 2004. The firm plans to combine Wyeth's 105-person dedicated U.S. sales force with its own 36-person U.S. team marketing Synvisc and Carticel autologous cultured chondrocytes for knee cartilage repair, extending its orthopedic market reach. Synvisc currently controls 65% of the U.S. viscosupplementation market. A U.S. hip trial is under way. Approved in the U.S. for knees in August 1997, Synvisc developer Biomatrix was acquired by Genzyme's Biosurgery division in 2000 (1"The Gray Sheet" March 13, 2000, p. 16)...
Genzyme Bid For Impath Unit Reflects Efforts To Raise Oncology Profile
Genzyme will gain access to an expanded menu of cancer diagnostic tests and physician services if a pending $215 mil. cash bid for Impath's cancer testing unit proves successful
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.